Tissue expression of PD-L1 mediates peripheral T cell tolerance ME Keir, SC Liang, I Guleria, YE Latchman, A Qipo, LA Albacker, ... The Journal of experimental medicine 203 (4), 883-895, 2006 | 1443 | 2006 |
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ... Cancer discovery 8 (7), 822-835, 2018 | 1259 | 2018 |
Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity YJ Chang, HY Kim, LA Albacker, N Baumgarth, ANJ McKenzie, DE Smith, ... Nature immunology 12 (7), 631-638, 2011 | 900 | 2011 |
Mechanisms and therapeutic implications of hypermutation in gliomas M Touat, YY Li, AN Boynton, LF Spurr, JB Iorgulescu, CL Bohrson, ... Nature 580 (7804), 517-523, 2020 | 455 | 2020 |
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers M Yarchoan, LA Albacker, AC Hopkins, M Montesion, K Murugesan, ... JCI insight 4 (6), 2019 | 423 | 2019 |
Innate lymphoid cells responding to IL-33 mediate airway hyperreactivity independently of adaptive immunity HY Kim, YJ Chang, S Subramanian, HH Lee, LA Albacker, ... Journal of Allergy and Clinical Immunology 129 (1), 216-227. e6, 2012 | 363 | 2012 |
Activation mechanism of oncogenic deletion mutations in BRAF, EGFR, and HER2 SA Foster, DM Whalen, A Özen, MJ Wongchenko, JP Yin, I Yen, ... Cancer cell 29 (4), 477-493, 2016 | 205 | 2016 |
Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer … M Radovich, G Jiang, BA Hancock, C Chitambar, R Nanda, C Falkson, ... JAMA oncology 6 (9), 1410-1415, 2020 | 199 | 2020 |
Influenza infection in suckling mice expands an NKT cell subset that protects against airway hyperreactivity YJ Chang, HY Kim, LA Albacker, HH Lee, N Baumgarth, S Akira, ... The Journal of clinical investigation 121 (1), 57-69, 2011 | 179 | 2011 |
Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response M Montesion, K Murugesan, DX Jin, R Sharaf, N Sanchez, A Guria, ... Cancer Discovery 11 (2), 282-292, 2021 | 159 | 2021 |
Pan-cancer landscape and analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity JP Robichaux, YY Elamin, RSK Vijayan, MB Nilsson, L Hu, J He, F Zhang, ... Cancer Cell 36 (4), 444-457. e7, 2019 | 158 | 2019 |
Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient … SHI Ou, J Cui, AB Schrock, ME Goldberg, VW Zhu, L Albacker, ... Lung cancer 108, 228-231, 2017 | 154 | 2017 |
Invariant natural killer T cells recognize a fungal glycosphingolipid that can induce airway hyperreactivity LA Albacker, V Chaudhary, YJ Chang, HY Kim, YT Chuang, M Pichavant, ... Nature medicine 19 (10), 1297-1304, 2013 | 153 | 2013 |
The genomic landscape of Merkel cell carcinoma and clinicogenomic biomarkers of response to immune checkpoint inhibitor therapy TC Knepper, M Montesion, JS Russell, ES Sokol, GM Frampton, VA Miller, ... Clinical Cancer Research 25 (19), 5961-5971, 2019 | 142 | 2019 |
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer MV Negrao, F Skoulidis, M Montesion, K Schulze, I Bara, V Shen, H Xu, ... Journal for immunotherapy of cancer 9 (8), 2021 | 141 | 2021 |
Comprehensive genomic profiling facilitates implementation of the national comprehensive cancer network guidelines for lung cancer biomarker testing and identifies patients who … JH Suh, A Johnson, L Albacker, K Wang, J Chmielecki, G Frampton, ... The Oncologist 21 (6), 684-691, 2016 | 122 | 2016 |
High-throughput genomic profiling of adult solid tumors reveals novel insights into cancer pathogenesis RJ Hartmaier, LA Albacker, J Chmielecki, M Bailey, J He, ME Goldberg, ... Cancer research 77 (9), 2464-2475, 2017 | 111 | 2017 |
TIM-4, a receptor for phosphatidylserine, controls adaptive immunity by regulating the removal of antigen-specific T cells LA Albacker, P Karisola, YJ Chang, SE Umetsu, M Zhou, O Akbari, ... The Journal of Immunology 185 (11), 6839-6849, 2010 | 106 | 2010 |
Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion LA Albacker, J Wu, P Smith, M Warmuth, PJ Stephens, P Zhu, L Yu, ... PloS one 12 (11), e0176181, 2017 | 97 | 2017 |
Deletion of the MAD2L1 spindle assembly checkpoint gene is tolerated in mouse models of acute T-cell lymphoma and hepatocellular carcinoma F Foijer, LA Albacker, B Bakker, DC Spierings, Y Yue, SZ Xie, S Davis, ... Elife 6, e20873, 2017 | 74 | 2017 |